JP2006516652A5 - - Google Patents

Download PDF

Info

Publication number
JP2006516652A5
JP2006516652A5 JP2006503317A JP2006503317A JP2006516652A5 JP 2006516652 A5 JP2006516652 A5 JP 2006516652A5 JP 2006503317 A JP2006503317 A JP 2006503317A JP 2006503317 A JP2006503317 A JP 2006503317A JP 2006516652 A5 JP2006516652 A5 JP 2006516652A5
Authority
JP
Japan
Prior art keywords
composition
peptide
amino acids
minimum
net positive
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Granted
Application number
JP2006503317A
Other languages
English (en)
Japanese (ja)
Other versions
JP4838114B2 (ja
JP2006516652A (ja
Filing date
Publication date
Application filed filed Critical
Priority claimed from PCT/US2004/003193 external-priority patent/WO2004070054A2/en
Publication of JP2006516652A publication Critical patent/JP2006516652A/ja
Publication of JP2006516652A5 publication Critical patent/JP2006516652A5/ja
Application granted granted Critical
Publication of JP4838114B2 publication Critical patent/JP4838114B2/ja
Anticipated expiration legal-status Critical
Expired - Lifetime legal-status Critical Current

Links

JP2006503317A 2003-02-04 2004-02-03 ミトコンドリア透過性転移の阻止方法 Expired - Lifetime JP4838114B2 (ja)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
US44477703P 2003-02-04 2003-02-04
US60/444,777 2003-02-04
US53569004P 2004-01-08 2004-01-08
US60/535,690 2004-01-08
PCT/US2004/003193 WO2004070054A2 (en) 2003-02-04 2004-02-03 Methods for preventing mitochondrial permeability transition

Related Child Applications (1)

Application Number Title Priority Date Filing Date
JP2010241738A Division JP5775285B2 (ja) 2003-02-04 2010-10-28 ミトコンドリア透過性転移の阻止方法

Publications (3)

Publication Number Publication Date
JP2006516652A JP2006516652A (ja) 2006-07-06
JP2006516652A5 true JP2006516652A5 (https=) 2007-10-18
JP4838114B2 JP4838114B2 (ja) 2011-12-14

Family

ID=32853391

Family Applications (7)

Application Number Title Priority Date Filing Date
JP2006503317A Expired - Lifetime JP4838114B2 (ja) 2003-02-04 2004-02-03 ミトコンドリア透過性転移の阻止方法
JP2010241738A Expired - Lifetime JP5775285B2 (ja) 2003-02-04 2010-10-28 ミトコンドリア透過性転移の阻止方法
JP2013182343A Expired - Lifetime JP5837542B2 (ja) 2003-02-04 2013-09-03 ミトコンドリア透過性転移の阻止方法
JP2014202889A Expired - Lifetime JP6126059B2 (ja) 2003-02-04 2014-10-01 ミトコンドリア透過性転移の阻止方法
JP2015135207A Expired - Lifetime JP6166312B2 (ja) 2003-02-04 2015-07-06 ミトコンドリア透過性転移の阻止方法
JP2017025764A Pending JP2017095519A (ja) 2003-02-04 2017-02-15 ミトコンドリア透過性転移の阻止方法
JP2019001256A Pending JP2019089773A (ja) 2003-02-04 2019-01-08 ミトコンドリア透過性転移の阻止方法

Family Applications After (6)

Application Number Title Priority Date Filing Date
JP2010241738A Expired - Lifetime JP5775285B2 (ja) 2003-02-04 2010-10-28 ミトコンドリア透過性転移の阻止方法
JP2013182343A Expired - Lifetime JP5837542B2 (ja) 2003-02-04 2013-09-03 ミトコンドリア透過性転移の阻止方法
JP2014202889A Expired - Lifetime JP6126059B2 (ja) 2003-02-04 2014-10-01 ミトコンドリア透過性転移の阻止方法
JP2015135207A Expired - Lifetime JP6166312B2 (ja) 2003-02-04 2015-07-06 ミトコンドリア透過性転移の阻止方法
JP2017025764A Pending JP2017095519A (ja) 2003-02-04 2017-02-15 ミトコンドリア透過性転移の阻止方法
JP2019001256A Pending JP2019089773A (ja) 2003-02-04 2019-01-08 ミトコンドリア透過性転移の阻止方法

Country Status (13)

Country Link
US (8) US7576061B2 (https=)
EP (9) EP1599216B9 (https=)
JP (7) JP4838114B2 (https=)
CN (3) CN104225574B (https=)
AU (1) AU2004209663B2 (https=)
CA (1) CA2515080C (https=)
CY (2) CY1114959T1 (https=)
DK (3) DK2656854T3 (https=)
ES (3) ES2540897T3 (https=)
HU (1) HUE027110T2 (https=)
PT (2) PT1599216E (https=)
SI (1) SI2656854T1 (https=)
WO (1) WO2004070054A2 (https=)

Families Citing this family (61)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP1599216B9 (en) * 2003-02-04 2015-02-11 Cornell Research Foundation, Inc. Methods for preventing mitochondrial permeability transition
PL2604286T3 (pl) * 2003-05-01 2015-03-31 Cornell Res Foundation Inc Sposoby i kompleksy nośnikowe do transportu cząsteczek do komórek
CA3024434A1 (en) * 2004-01-23 2005-08-11 Cornell Research Foundation, Inc. Methods for reducing oxidative damage
CN104788540B (zh) * 2005-09-16 2019-10-18 科内尔研究基金会 用于减少cd36表达的方法
AU2014203126B2 (en) * 2005-09-16 2016-03-10 Cornell Research Foundation, Inc. Methods for reducing cd36 expression
EP2712620A1 (en) 2008-02-07 2014-04-02 Cornell University Methods for Preventing or Treating Insulin Resistance
EP3741381B1 (en) 2008-02-26 2024-04-24 Cornell University A peptide for use for prevention and treatment of acute renal injury
DE102008061044A1 (de) * 2008-12-11 2010-06-17 Henkel Ag & Co. Kgaa Zusammensetzung mit antioxidativ wirksamen Peptiden
US20100331265A1 (en) * 2009-03-20 2010-12-30 Tompkins Ronald G Methods for the prevention and treatment of burn injuries and secondary complications
WO2011019809A1 (en) * 2009-08-12 2011-02-17 Cornell University Methods for preventing or treating metabolic syndrome
ES2964555T3 (es) 2009-08-24 2024-04-08 Stealth Biotherapeutics Inc Péptido para uso en la prevención o tratamiento de la degeneración macular
WO2011044044A1 (en) * 2009-10-05 2011-04-14 Cornell University Methods for the prevention or treatment of heart failure
EP3266462A1 (en) * 2009-12-31 2018-01-10 Stealth Peptides International, Inc. Methods for performing a coronary artery bypass graft procedure
EP3090754A1 (en) * 2009-12-31 2016-11-09 Stealth Peptides International, Inc. Methods for the prevention or treatment of vessel occlusion injury
CA2787331A1 (en) * 2010-01-25 2011-07-28 Hazel H. Szeto Aromatic-cationic peptides and uses of same
JP2013521231A (ja) * 2010-02-26 2013-06-10 ユニバーシティ オブ フロリダ リサーチ ファウンデーション インコーポレイテッド ミトコンドリア標的化抗酸化剤は機械的人工呼吸誘発性横隔膜機能障害および骨格筋萎縮を防止する
EP3375449A1 (en) * 2010-03-15 2018-09-19 Stealth Peptides International, Inc. Combination therapies using cyclosporine and aromatic cationic peptides
US20110245182A1 (en) 2010-04-06 2011-10-06 Perricone Nicholas V Topical Uses of Szeto-Schiller Peptides
US20110245183A1 (en) 2010-04-06 2011-10-06 Perricone Nicholas V Topical Uses of Szeto-Schiller Peptides
EP3290433A1 (en) * 2010-05-03 2018-03-07 Stealth Peptides International, Inc. Aromatic-cationic peptides and uses of same
WO2014137496A1 (en) * 2013-03-08 2014-09-12 The Administrators Of The Tulane Educational Fund Mu opioid receptor agonist analogs of the endomorphins
EP2590664B1 (en) * 2010-07-09 2019-03-27 Stealth Peptides International, Inc. Methods for the prevention or treatment of no-reflow following ischemia/reperfusion injury
US20160176930A1 (en) 2010-07-09 2016-06-23 The Administrators Of The Tulane Educational Fund Mu opioid receptor agonist analogs of the endomorphins
US20120083452A1 (en) 2010-09-30 2012-04-05 Perricone Nicholas V Topical Anesthetic Uses of Szeto-Schiller Peptides
EP3108975A1 (en) * 2011-03-24 2016-12-28 Cornell University Aromatic-cationic peptides and uses of same
WO2013043580A2 (en) 2011-09-19 2013-03-28 Gencia Corporation Modified creatine compounds
CN106913860A (zh) 2011-09-29 2017-07-04 梅约医学教育与研究基金会 芳族阳离子肽和使用它们的方法
HK1201443A1 (en) * 2011-10-17 2015-09-04 Cornell University Aromatic-cationic peptides and uses of same
EP2788013A4 (en) * 2011-12-09 2015-08-19 Stealth Peptides Int Inc AROMATIC-CATIONIC PEPTIDES AND USES THEREOF
CN104271146A (zh) 2012-03-30 2015-01-07 康肽德生物医药技术有限公司 用于预防和治疗神经病的方法和组合物
JP2015529655A (ja) * 2012-08-02 2015-10-08 ステルス ペプチドズ インターナショナル インコーポレイテッド アテローム性硬化症の処置方法
AU2013334788A1 (en) * 2012-10-22 2015-06-04 Henry Ford Health Systems Methods for reducing risks associated with heart failure and factors associated therewith
ES2755134T3 (es) 2013-03-01 2020-04-21 Stealth Biotherapeutics Corp Métodos para el tratamiento de enfermedad mitocondrial
US9687519B2 (en) 2013-03-01 2017-06-27 Stealth Biotherapeutics Corp Methods and compositions for the prevention or treatment of barth syndrome
EP2989120A4 (en) 2013-04-25 2017-04-19 Carmel-Haifa University Economic Corp. Synthetic anti-inflammatory peptides and use thereof
CA2916977A1 (en) 2013-06-26 2014-12-31 Stealth Biotherapeutics Corp Methods and compositions for detecting and diagnosing diseases and conditions
CA2919992C (en) * 2013-08-01 2022-08-09 Stealth Biotherapeutics Corp Methods and compositions for preventing or treating leber's hereditary optic neuropathy
WO2015017861A1 (en) 2013-08-02 2015-02-05 Stealth Peptides International, Inc. Methods and compositions for the prevention and treatment of friedreich's ataxia
EP3052115A4 (en) * 2013-09-30 2017-09-27 Cornell University Cardiolipin-targeted peptides inhibit beta-amyloid oligomer toxicity
CN106536056B (zh) 2014-06-13 2021-07-16 儿童医学中心公司 分离线粒体的产品和方法
EP3160984B1 (en) 2014-06-25 2021-04-14 Flamma S.P.A. Process for preparing d-arginyl-2,6-dimethyl-l-tyrosyl-l-lysyl-l-phenylalaninamide
WO2016001042A1 (en) 2014-06-30 2016-01-07 Flamma S.P.A. Process for the production of d-arginyl-2,6-dimethyl-l-tyrosyl-l-lysyl-l-phenylalaninamide
WO2016004093A2 (en) * 2014-07-01 2016-01-07 Stealth Biotherapeutics Corp Therapeutic compositions including galectin-3 inhibitors and uses thereof
CN104306954B (zh) * 2014-09-25 2016-08-24 中山大学 Wry三肽在制备治疗阿尔茨海默症药物中的用途
EP3212194A4 (en) 2014-10-29 2018-06-20 University Of Maryland Methods of treating age-related symptoms in mammals and compositions therefor
WO2017015660A1 (en) * 2015-07-23 2017-01-26 Salk Institute For Biological Studies Prevention and treatment of aging and neurodegenerative diseases
CA3006698A1 (en) * 2015-11-30 2017-06-08 Peter Schiller Aromatic-cationic peptides conjugated to antioxidants and their use in treating complex regional pain syndrome
WO2017124037A1 (en) 2016-01-15 2017-07-20 The Children's Medical Center Corporation Therapeutic use of mitochondria and combined mitochondrial agents
CA3017359A1 (en) 2016-03-11 2017-09-14 Scott M. Duncan Crystalline salt forms
WO2017180535A1 (en) 2016-04-11 2017-10-19 Carnot, Llc Chiral peptides
KR20190088520A (ko) 2016-11-30 2019-07-26 주식회사 다이셀 촬상 장치용 렌즈 모듈 및 그의 제조 방법
US11034724B2 (en) 2017-04-05 2021-06-15 Stealth Biotherapeutics Corp. Crystalline salt forms of Boc-D-Arg-DMT-Lys-(Boc)-Phe-NH2
WO2019033330A1 (en) 2017-08-17 2019-02-21 Xw Laboratories, Inc. PREPARATION AND USES OF DERIVATIVES TRACERS OF OXYGEN REACTIVE SPECIES
EP3679051B1 (en) 2017-09-04 2021-12-29 XWPharma Ltd. Preparation and use of reactive oxygen species scavenger
JP6958860B2 (ja) * 2017-11-07 2021-11-02 学校法人自治医科大学 ミトコンドリアの機能障害の改善剤、及びミトコンドリアの機能障害に起因する疾患又は症状の予防又は治療薬、並びにそれらの用途
US10676506B2 (en) 2018-01-26 2020-06-09 Stealth Biotherapeutics Corp. Crystalline bis- and tris-hydrochloride salt of elamipretide
IL284006B2 (en) * 2018-12-18 2024-12-01 Stealth Biotherapeutics Corp Mitochondria-targeting peptides
WO2020222866A1 (en) * 2019-05-02 2020-11-05 Children's Medical Center Corporation Prophylactic and therapeutic use of mitochondria and combined mitochondrial agents
EP3771467A1 (en) 2019-07-30 2021-02-03 Fundacio Institut de Recerca de l'Hospital de la Santa Creu i sant Pau Ss-31 for the prevention and/or treatment of aneurysm
CN116390723B (zh) * 2020-09-09 2024-12-31 社会利益网络公司 用于将生物素递送至线粒体的方法和组合物
CN117881411A (zh) 2021-06-01 2024-04-12 艾迪雅生物有限责任公司 用于眼部药物的延长释放药物递送系统和使用方法

Family Cites Families (39)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4522811A (en) 1982-07-08 1985-06-11 Syntex (U.S.A.) Inc. Serial injection of muramyldipeptides and liposomes enhances the anti-infective activity of muramyldipeptides
US5602100A (en) 1988-06-30 1997-02-11 Astra Ab Dermorphin analogs having pharmacological activity
SG64368A1 (en) 1988-06-30 1999-04-27 Astra Ab Dermorphin analogs their methods of preparation pharmaceutical compositions and methods of therapeutic treatment using the same
US5670617A (en) * 1989-12-21 1997-09-23 Biogen Inc Nucleic acid conjugates of tat-derived transport polypeptides
AU659795B2 (en) * 1990-01-17 1995-06-01 Regents Of The University Of California, The Composition to improve survival of biological materials
US5858784A (en) 1991-12-17 1999-01-12 The Regents Of The University Of California Expression of cloned genes in the lung by aerosol- and liposome-based delivery
US5674534A (en) 1992-06-11 1997-10-07 Alkermes, Inc. Composition for sustained release of non-aggregated erythropoietin
US5716644A (en) 1992-06-11 1998-02-10 Alkermes, Inc. Composition for sustained release of non-aggregated erythropoietin
IS4261A (is) 1994-02-21 1995-08-22 Astra Aktiebolag Nýir peptíð-ópíóíðar til meðhöndlunar á verkjum og notkun þeirra
ATE255450T1 (de) * 1995-06-09 2003-12-15 Hisamitsu Pharmaceutical Co Matrix für iontophorese
US5849761A (en) * 1995-09-12 1998-12-15 Regents Of The University Of California Peripherally active anti-hyperalgesic opiates
DE69722258T2 (de) * 1996-10-07 2004-03-18 Eli Lilly And Co., Indianapolis Neue verbindungen nutlich als neuroschützende mittel
US5885958A (en) * 1997-03-25 1999-03-23 Administrators Of The Tulane Educational Fund Mu-opiate receptor peptides
US5989463A (en) 1997-09-24 1999-11-23 Alkermes Controlled Therapeutics, Inc. Methods for fabricating polymer-based controlled release devices
WO1999029721A1 (en) * 1997-12-10 1999-06-17 Washington University Anti-pathogen system and methods of use thereof
WO1999055321A1 (en) * 1998-04-24 1999-11-04 Mitokor Compounds and methods for treating mitochondria-associated diseases
US6472378B2 (en) * 1998-08-31 2002-10-29 Pro-Neuron, Inc. Compositions and methods for treatment of mitochondrial diseases
US6245740B1 (en) 1998-12-23 2001-06-12 Amgen Inc. Polyol:oil suspensions for the sustained release of proteins
GB9905503D0 (en) * 1999-03-10 1999-05-05 Adprotech Plc Novel compound formulations and methods of delivery
SE9900961D0 (sv) 1999-03-16 1999-03-16 Astra Ab Novel compounds
DE60042338D1 (de) * 1999-10-04 2009-07-16 Univ New Jersey Med TAR RNA bindende Peptide
US6759520B1 (en) * 1999-10-28 2004-07-06 The New England Medical Center Hospitals, Inc. Chimeric analgesic peptides
US20050192215A1 (en) 2000-01-21 2005-09-01 Malabika Ghosh Methods and materials relating to novel polypeptides and polynucleotides
US7498297B2 (en) * 2000-07-18 2009-03-03 Cornell Research Foundation Medicinal uses of mu-opioid receptor agonists
US6900178B2 (en) * 2000-09-12 2005-05-31 University Of Kentucky Research Foundation Protection against ischemia and reperfusion injury
EP1339668A2 (en) * 2000-11-28 2003-09-03 Guilford Pharmaceuticals Inc. Bisubstituted carbocyclic cyclophilin binding compounds and theirus
US6545097B2 (en) * 2000-12-12 2003-04-08 Scimed Life Systems, Inc. Drug delivery compositions and medical devices containing block copolymer
US6656971B2 (en) * 2001-01-25 2003-12-02 Guilford Pharmaceuticals Inc. Trisubstituted carbocyclic cyclophilin binding compounds and their use
US20030077826A1 (en) * 2001-02-02 2003-04-24 Lena Edelman Chimeric molecules containing a module able to target specific cells and a module regulating the apoptogenic function of the permeability transition pore complex (PTPC)
WO2002066095A2 (en) * 2001-02-16 2002-08-29 Cordis Corporation Method of balloon catheter stent delivery system with ridges
AU2002252372A1 (en) * 2001-03-16 2002-10-03 Sts Biopolymers, Inc. Stent with medicated multi-layer hydrid polymer coating
JPWO2002102833A1 (ja) * 2001-06-15 2004-09-30 千寿製薬株式会社 新規エンドモルフィン誘導体
EP1599216B9 (en) * 2003-02-04 2015-02-11 Cornell Research Foundation, Inc. Methods for preventing mitochondrial permeability transition
CN101440124B (zh) * 2003-02-04 2012-07-18 科内尔研究基金会 用于防止线粒体通透性改变的方法
PL2604286T3 (pl) 2003-05-01 2015-03-31 Cornell Res Foundation Inc Sposoby i kompleksy nośnikowe do transportu cząsteczek do komórek
JP2005005762A (ja) * 2003-06-09 2005-01-06 Fujitsu Ltd 送信電力制御方法及び装置
WO2005032481A2 (en) 2003-09-30 2005-04-14 Scios Inc. Quinazoline derivatives as medicaments
CA3024434A1 (en) * 2004-01-23 2005-08-11 Cornell Research Foundation, Inc. Methods for reducing oxidative damage
CN104788540B (zh) 2005-09-16 2019-10-18 科内尔研究基金会 用于减少cd36表达的方法

Similar Documents

Publication Publication Date Title
JP2006516652A5 (https=)
CA2515080A1 (en) Methods for preventing mitochondrial permeability transition
RU2006130431A (ru) Способ уменьшения окислительного повреждения (варианты)
JP2007518818A5 (https=)
US6320024B1 (en) Method for design of substances that enhance memory and improve the quality of life
US9023986B2 (en) Glucose-dependent insulinotropic peptide analogs
JP2003503312A5 (https=)
WO2002026774A2 (en) Melanocortin receptor ligands
AU2001296313A1 (en) Melanocortin receptor ligands
IL191636A (en) Neurolipeptide-2 receptor agonists, medicinal preparations containing them and their use in the preparation of drugs
CN102574894A (zh) 稳定化的黑皮质素配体
RU2010111114A (ru) Нейропротективное действие с применением nap-подобных и sal-подобных пептидных миметиков
US9611297B1 (en) Compositions and methods for the treatment of cast nephropathy and related conditions
Yasuda-Kamatani et al. A novel D-amino acid-containing peptide, fulyal, coexists with fulicin gene-related peptides in Achatina atria
US8415292B2 (en) Compositions and methods for inhibiting the interaction between CFTR and CAL
JP2009519212A5 (https=)
CA2769013C (en) Motilin-like peptide compound having transmucosal absorbability imparted thereto
M Cowell et al. Biphalin: the foundation of bivalent ligands
JP6795258B2 (ja) 医薬化合物
IE903958A1 (en) Reduced irreversible bombesin antagonists
Mukai et al. Structure-activity relationships of mammalian bombesin-like neuropeptides in the contraction of rat uterus
Mansfeld et al. Synthesis and plasma stability of disulfide-bridged cyclic endomorphin-1 derivatives
US20030032774A1 (en) Novel opioid peptides for the treatment of pain
US7314867B2 (en) Pharmaceutical composition comprising a retro-iverso isomer peptide
JP2015151386A (ja) 新規生理活性ペプチド及びその用途